Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

• Published in: Molecular cancer therapeutics Vol. 7; no. 3; pp. 638 - 647
• Main Authors: Laquente, Berta, Lacasa Salavert, Cristina, Ginestà, Mireia M, Casanovas i Casanovas, Oriol, Figueras i Amat, Agnès, Galán, Maica, García Ribas, Ignacio, Germà Lluch, José Ramón, Capellá, G. (Gabriel), Viñals Canals, Francesc
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01-03-2008
• Subjects: Angiogenesis Inhibitors - pharmacology; Angiogènesi; Animals; anti-angiogenesis; Antineoplastic agents; Antineoplastic Agents - pharmacology; Cancer chemotherapy; Cells, Cultured; Càncer de pàncrees; Deoxycytidine - analogs & derivatives; Deoxycytidine - pharmacology; Disease Models, Animal; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Medicaments antineoplàstics; metronomic chemotherapy; Mice; Mice, Nude; Neovascularization; Pancreas cancer; Pancreatic Neoplasms - blood supply; Quimioteràpia del càncer; xenograft pancreatic model
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-07-2122

Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article,
we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that
involves the regular administration of cytotoxic drugs at doses lower than standard treatment. In vitro results showed that human endothelial cells are more sensitive to gemcitabine (IC 50 3 nmol/L) than pancreatic tumor cells (IC 50 20 nmol/L). For in vivo studies, we used an orthotopic implantation model of human pancreatic carcinoma in nude mice. Gemcitabine was administered
i.p. following a low-dose schedule (1 mg/kg/d for a month) and compared with the conventional schedule (100 mg/kg days 0,
3, 6, and 9 postimplantation). Metronomic treatment effect on established tumor was equivalent to standard administration.
The measure of CD31 endothelial marked area allowed us to show an in vivo antiangiogenic effect of this drug that was further enhanced by using metronomic administration. This effect correlated with
an induction of thrombospondin-1, a natural inhibitor of angiogenesis. Our results allow us to hypothesize that, in addition
to a direct antiproliferative or cytotoxic antiendothelial cell effect, a secondary effect involving thrombospondin-1 induction
might provide an explanation for the specificity of the effects of metronomic gemcitabine treatment. [Mol Cancer Ther 2008;7(3):638–47]